Abstract
Background: Liraglutide is a glucagon-like 1 (GLP-1) agonist approved for treatment of type 2 diabetes and obesity. Objective: To review the cardiovas......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
